Reducing the risk of SUDEP
- 3 November 2020
- journal article
- editorial
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 95 (18), 807-808
- https://doi.org/10.1212/wnl.0000000000010916
Abstract
It was not that long ago that some believed there was little point in discussing sudden unexpected death in epilepsy (SUDEP) with patients. Why cause anxiety, it was argued, if the risk could not be influenced? The results of the landmark study by Sveinsson et al.(1-3) reporting on a nationwide population-based case-control study of 255 SUDEP cases from Sweden, the largest so far, which combines data from linked records with detailed review of medical charts, suggest otherwise.This publication has 10 references indexed in Scilit:
- Pharmacologic treatment and SUDEP riskNeurology, 2020
- Clinical risk factors in SUDEPNeurology, 2020
- Refractory epilepsy and nonadherence to drug treatmentEpilepsia Open, 2019
- SUDEP in the North American SUDEP RegistryNeurology, 2019
- Risks and predictive biomarkers of sudden unexpected death in epilepsy patientCurrent Opinion in Neurology, 2019
- Circumstances of SUDEP: A nationwide population‐based case seriesEpilepsia, 2018
- Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trialsThe Lancet Neurology, 2011
- Epilepsy mortality and risk factors for death in epilepsy: a population-based studyBritish Journal of General Practice, 2011
- Serotonin reuptake inhibitors are associated with reduced severity of ictal hypoxemia in medically refractory partial epilepsyEpilepsia, 2010
- Nonadherence to antiepileptic drugs and increased mortalityNeurology, 2008